new glp retatrutide Warning: What GLP-1 Providers Must Know Now Retatrutide - Find Top Weight

GLP-1s workbut even great therapies can hit a ceiling

For these patients, a medication that addresses both concerns simultaneously is ideal

Mohammadzadeh V, Atapour-Mashhad H, Shahvali S, Salehi B, Shaban M, Shirzad M, et al

territories or international addresses

TeleSlim emphasizes doctor-led care with board-certified obesity medicine physicians, virtual convenience, personalized plans, and clear affordability examples in public listings highlight starter pricing as low as $99/month and discounted multi-month plans (3-, 6-, 12-month)

Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts